The data shown on this page comes from Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries.
When it comes to CMO selection, Executive Management and Manufacturing/Production hold the most influence over the decision, each accounting for ~20% of control.
Eighty-seven percent of global biosimilar sales come from the E.U., compared to just 2 percent from the U.S. We asked outsourced biomanufacturing decision-makers from North America and Europe to share their companies’ stances on selling and manufacturing biosimilars.
The use of electronic data collection tools is prevalent across clinical trial phases. Respondents with visibility into Phase 4 studies report 90 to 96% of these studies use electronic data capture tools, either exclusively or as part of a hybrid EDC/paper strategy.
The 10th Edition of ISR’s CRO Quality Benchmarking Suite comes out this year. Here we take a look at how the CRO landscape has changed throughout the past decade.
Integration with eClinical software applications will drive IRT (interactive response technology) enhancements, but it is important to many study sponsors that IRT be delivered though companies that specialize in this technology.
What is the effect of a near-record volume of drug approvals? Just think about the potential impact on manufacturing, market access, late-phase clinical development, and sales and marketing activities.
Using data from several market research reports, Industry Standard Research analyzed preferred provider arrangements across clinical development, eClinical, and contract manufacturing industries. Go to ISRreports.com/free-industry-resources to see the full infographic, which includes data for the contract manufacturing and eClinical markets.
Industry Standard Research (ISR), a full-service market research provider to the pharma and pharma services industries, has collected information from outsourcing decision makers via an online survey regarding their selection and evaluation of CROs.
Over the past several decades, the practice of outsourcing has evolved from transactional, client-vendor relationships where cost savings were the primary focus, to preferred provider relationships with pre-vetted companies to start up projects quickly and then to relationships more strategic in nature to gain access to technologies, skills, or expertise not possessed in-house.
Lou Schmukler, president of global product development and supply at Bristol-Myers Squibb, explains some of the nuances between small and large molecule drug manufacturing.
Tony Coles, M.D., former CEO of Onyx Pharmaceuticals, provides his perspective on Amgen’s $9.7 billion acquisition of Onyx.
Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.
Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.